| Literature DB >> 33786259 |
Farid Meybodi1, Negin Sedaghat1, Elisabeth Elder1, James French1, Kristian Adams1, Jeremy Hsu1, Kavitha Kanesalingam1, Meagan Brennan1.
Abstract
Severe infections of implant-based breast reconstruction are challenging to treat. Traditional management is removal of the implant with a further attempt at reconstruction months later once the infection has settled. This study evaluates an alternative management protocol using negative pressure wound therapy with instillation (NPWTi).Entities:
Year: 2021 PMID: 33786259 PMCID: PMC7997091 DOI: 10.1097/GOX.0000000000003456
Source DB: PubMed Journal: Plast Reconstr Surg Glob Open ISSN: 2169-7574
Fig. 1.A 43-year-old woman underwent bilateral nipple-sparing mastectomy and direct-to-implant reconstruction with sub-pectoral implants. A, Immediate postoperative result. B, Severe peri-prosthetic infection in the right breast on postoperative day 17 with frank pus in the implant pocket and a culture that grew methicillin-sensitive staphylococcus aureus (MSSA). C, Clean breast pocket after 3 days of negative pressure wound therapy with installation (NPWTi). D, After 7 days of NPWTi, culture was taken, which showed eradication of infection. E, Result following insertion of tissue expander at the completion of NPWTi. F, Final result after exchange of tissue expander for permanent prosthesis.
Patient Demographics (n = 28 Patients; n = 30 Breasts)
| Characteristic | n | % | |
|---|---|---|---|
| Age (y) | Mean | 43.4 | NA |
| Median | 43 | NA | |
| Range | 34–57 | NA | |
| Smoking status | Current smoker | 1 | 3.6 |
| Previous smoker | 4 | 14.3 | |
| Never smoker | 20 | 71.4 | |
| Unknown | 3 | 10.7 | |
| Diabetes | Yes | 0 | 0 |
| No | 30 | 100 | |
| Connective tissue disease | Yes | 2 | 7.1 |
| No | 26 | 92.9 | |
| Previous radiotherapy | Yes | 2 | 6.6 |
| No | 28 | 93.3 | |
*Not retrieved from review of medical record.
Initial Breast Reconstruction Surgery (n = 30 Breasts)
| Characteristic | n | % | |
|---|---|---|---|
| Indication for mastectomy | Invasive cancer | 17 | 56.7 |
| DCIS | 4 | 13.3 | |
| Risk-reducing | 9 | 30 | |
| Timing of reconstruction | Immediate | 30 | 100 |
| Delayed | 0 | 0 | |
| Initial prosthesis type | Tissue expander | 16 | 53.3 |
| Direct to implant | 14 | 46.7 | |
| Placement of prosthesis | Sub-pectoral | 25 | 83.3 |
| Pre-pectoral | 5 | 16.7 | |
| Coverage of implant | Synthetic | 17 | 56.7 |
| Biologic | 6 | 20.0 | |
| Autologous | 5 | 16.7 | |
| None | 2 | 6.7 | |
| Initial prosthesis size (g/mL) | Mean | 350 | NA |
| Median | 335 | NA | |
| Range | 100–650 | NA | |
| Unknown | 4 | 13.3 |
*Synthetic mesh included TiLOOP Bra, TiLOOP Bra Pocket, SERI Surgical Scaffold, and TIGR Matrix.
†Biologic mesh included the following Acellular Dermal Matrices—Veritas, Strattice, FlexHD, and Biodesign.
‡Autologous included lipodermal flap.
§Not retrieved from review of medical record.
Features at Presentation with Infection (n = 30 Breasts)
| Characteristic | n | % | |
|---|---|---|---|
| Breasts affected | Unilateral | 25 | 83.3 |
| Bilateral | 5 | 16.7 | |
| Days from reconstruction to infection | Mean | 49.5 | NA |
| Median | 23 | NA | |
| Range | 7–420 | NA | |
| White cell count at presentation | Mean | 9.0 | NA |
| Median | 7.9 | NA | |
| Range | 1.8–24.7 | NA | |
| Not requested | 3 | 10 | |
| C-Reactive protein at presentation (mg/L) | Mean | 75.0 | NA |
| Median | 37.0 | NA | |
| Range | 2–380 | NA | |
| Not requested | 2 | 6.7 | |
| Organisms identified on culture | MSSA | 9 | 30.0 |
| 4 | 13.3 | ||
| MRSA | 2 | 6.7 | |
| 2 | 6.7 | ||
| Multiple organisms | 3 | 10.0 | |
| Other organisms | 6 | 20.0 | |
| No growth | 1 | 3.3 | |
| Unknown | 3 | 10.0 | |
*methicillin-sensitive Staphylococcus aureus.
†methicillin-resistant Staphylococcus aureus.
±Brevibacterium casei, Corynebacterium imitans, Enterococcus faecalis, Staphylococcus haemolyticus, Klebsiella oxytoca, and Proteus mirabilis.
§Not retrieved from review of medical record.
Treatment Information, Negative Pressure Wound Therapy with Instillation (n = 30 Breasts)
| Characteristic | n | % | |
|---|---|---|---|
| No. operations | Mean | 3.7 | NA |
| Median | 3 | NA | |
| Range | 2–7 | NA | |
| Days to negative culture | Mean | 5.2 | NA |
| Median | 4 | NA | |
| Range | 1–14 | NA | |
| Unknown | 4 | 13.3 | |
| Length of hospital stay (d) | Mean | 11.5 | NA |
| Median | 12 | NA | |
| Range | 6–22 | NA | |
| Unknown | 3 | 10.0 | |
| Irrigation solution | Normal saline | 11 | 36.7 |
| Acetic acid 1% | 4 | 13.3 | |
| Prontosan | 2 | 6.7 | |
| Unknown | 13 | 43.3 | |
| Prosthesis type in situ at presentation | Implant | 17 | 56.7 |
| Tissue expander | 13 | 43.3 | |
| Prosthesis type inserted at completion of NPWTi treatment | Implant | 5 | 16.7 |
| Tissue expander | 24 | 80.0 | |
| Success of implant salvage | Successful | 25 | 83.0 |
| Not successful | 5 | 17.0 | |
*Not retrieved from review of medical record.